Maximilian Winter

Established in 2018, xCures is a pioneer in healthcare data management. Our primary focus is on achieving data completeness and providing real-time data access. We gather and standardize detailed medical records from various healthcare sources, utilizing direct retrieval from US institutions, patient portals, and electronic health exchanges. The collected data is digitized, organized, and examined using Natural Language Processing to efficiently identify features, resulting in a comprehensive longitudinal patient journey that covers everything from genomics to social determinants of health. We have processed over 140 million records from thousands of different medical practices and implemented our technology for a significant number of patients. All the collected data elements are thoroughly annotated in a central Electronic Data Capture (EDC) system to ensure standardization and ongoing accuracy. Through a range of tools and products, xCures offers clinically actionable, real-time insights that support the care of patients, providers, and partners. For further information, please contact info@xcures.com or visit http://www.xcures.com.

Ancilia is harnessing the natural power of CRISPR to develop a new class of bacterial therapies and products for a range of applications.

We are an advanced biomaterials and biofabrication company.

The remarkable specificity and safety of antibody drugs have been limited to blocking inactivators for the largest class of drug targets. Abalone Bio develops antibody drugs that activate, enabling us to turn on previously inaccessible biological activities like anti-cancer or anti-inflammatory actions.

Decoding Secreted Proteins for Chronic and Age-Related Diseases

Pragma Bio exists to find cures for undruggable immunological disorders. We use real-world data and synthetic biology to map out multi-layered biological signatures associated with clinical outcomes in order to produce natural chemistry with therapeutic potential.

Bioz is the world’s most advanced AI search engine for products that are backed by science, with evidence-based product ratings and recommendations to guide users toward the most-validated products. Bioz solutions for suppliers include Bioz Badges and Content Hubs, web-based widgets, that are placed on product supplier websites to increase user engagement and sales conversion.

Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.

Precision. Clarity. Control. SentiAR is digital health, software company adding a new dimension to clinical practice in interventional procedures. Spun out of Washington University, we have developed the first 3D visualization platform using real time holography of the patients anatomy and catheter location with a goal to empower clinicians with more control and better precision to provide safer delivery of care.

ATLAS Space Operations is the leading provider of Ground Software as a Service™ in the space communications industry. ATLAS’ revolutionary Freedom™ software has been recognized by industry leading publications and organizations such as Via Satellite and the World Teleport Association. Additionally, ATLAS was highlighted in the CIO Review: Telecom Edition as Company of the Year (2023) as well as one of the 10 Most Promising Technologies. Lastly, Aerospace & Defense Review acknowledged ATLAS as one of the Top Satellite Solutions Providers. ATLAS combines the Freedom™ Software Platform and its global antenna network to achieve its mission of securing space access anytime, anywhere. To learn more, visit atlasspace.com.

GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA.

Sana is a digital health company driven by 25 years of research. The innovative audiovisual technology allows you to accelerate your physical recovery and improve your mental well-being, offering a more restful state of mind. The Sana device is not currently approved by the FDA for any medical condition and should be used for the purposes of rest and recovery only, until such time as appropriate clinical evidence is approved through FDA processes.

We are an indoor aquaponic farm growing organic leafy greens & sustainable fish with the highest ecological standards to reconnect eaters with flavorful, nutritious, local food.

Terramera is a cleantech leader focused on fusing AI, science and nature to create revolutionary technologies that transform how we grow food and solve other world-scale challenges. With its Actigate™ Targeted Performance technology and mission to unlock the intelligence in nature to ensure a world that thrives and provides for everyone, Terramera is committed to reducing global synthetic chemical loads in agriculture by 80 percent while increasing global farm productivity by 20 percent by 2030. The privately held company was founded in 2010, and has grown to include a world-class bench of engineers, scientists, advisors and investors.

At Unlimited Tomorrow we empower individuals with upper limb differences by making high quality, affordable bionic prosthetic arms accessible to everyone who needs them.

Established in 2018, xCures is a pioneer in healthcare data management. Our primary focus is on achieving data completeness and providing real-time data access. We gather and standardize detailed medical records from various healthcare sources, utilizing direct retrieval from US institutions, patient portals, and electronic health exchanges. The collected data is digitized, organized, and examined using Natural Language Processing to efficiently identify features, resulting in a comprehensive longitudinal patient journey that covers everything from genomics to social determinants of health. We have processed over 140 million records from thousands of different medical practices and implemented our technology for a significant number of patients. All the collected data elements are thoroughly annotated in a central Electronic Data Capture (EDC) system to ensure standardization and ongoing accuracy. Through a range of tools and products, xCures offers clinically actionable, real-time insights that support the care of patients, providers, and partners. For further information, please contact info@xcures.com or visit http://www.xcures.com.

Ancilia is harnessing the natural power of CRISPR to develop a new class of bacterial therapies and products for a range of applications.

We are an advanced biomaterials and biofabrication company.

The remarkable specificity and safety of antibody drugs have been limited to blocking inactivators for the largest class of drug targets. Abalone Bio develops antibody drugs that activate, enabling us to turn on previously inaccessible biological activities like anti-cancer or anti-inflammatory actions.

Decoding Secreted Proteins for Chronic and Age-Related Diseases